High rate of survival in transformed lymphoma after autologous stem cell transplant: Pathologic analysis and comparison with de novo diffuse large B-cell lymphoma

Stephen D. Smith, Brian J. Bolwell, Anjali S. Advani, Steven W. Andresen, Josephine L. Chan, Robert M. Dean, Eric D. Hsi, Matt E. Kalaycio, Brad L. Pohlman, Lisa A. Rybicki, John W. Sweetenham

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Transformed lymphoma (TL) is historically associated with a poor prognosis, though autologous stem cell transplantation (ASCT) has been applied successfully. Better patient selection is needed for this intensive therapy. We analyzed the outcomes between de novo and transformed large B-cell lymphoma in patients undergoing ASCT, with regard to the immunohistochemical (IHC) features of potential prognostic utility including CD10, BCL6, MUM-1, Ki67, and BCL2. Of all patients undergoing ASCT for large B-cell lymphoma at the Cleveland Clinic Taussig Cancer Institute between 2003 and 2008, 56 patients (31 de novo and 25 TL) had undergone detailed IHC analysis. Three-year relapse-free-survival (RFS) and overall survival (OS) for TLvs. patients with de novo large B-cell lymphoma were 64%vs. 59% and 63%vs. 59%, respectively. More patients with TL were characterized as germinal-center B cell-of-origin (92%) than patients with de novo large B-cell lymphoma (71%). Immunohistochemistry did not predict relapse-free or overall survival, and ASCT afforded a high rate of PFS in patients with TL.

Original languageEnglish (US)
Pages (from-to)1625-1631
Number of pages7
JournalLeukemia and Lymphoma
Volume50
Issue number10
DOIs
StatePublished - Nov 11 2009
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Lymphoma
Stem Cells
Survival Rate
Transplants
Stem Cell Transplantation
B-Cell Lymphoma
Survival
Recurrence
Germinal Center
Patient Selection
B-Lymphocytes
Immunohistochemistry
Neoplasms

Keywords

  • Clinical results
  • Lymphoma and hodgkin disease
  • Prognostication

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

High rate of survival in transformed lymphoma after autologous stem cell transplant : Pathologic analysis and comparison with de novo diffuse large B-cell lymphoma. / Smith, Stephen D.; Bolwell, Brian J.; Advani, Anjali S.; Andresen, Steven W.; Chan, Josephine L.; Dean, Robert M.; Hsi, Eric D.; Kalaycio, Matt E.; Pohlman, Brad L.; Rybicki, Lisa A.; Sweetenham, John W.

In: Leukemia and Lymphoma, Vol. 50, No. 10, 11.11.2009, p. 1625-1631.

Research output: Contribution to journalArticle

Smith, SD, Bolwell, BJ, Advani, AS, Andresen, SW, Chan, JL, Dean, RM, Hsi, ED, Kalaycio, ME, Pohlman, BL, Rybicki, LA & Sweetenham, JW 2009, 'High rate of survival in transformed lymphoma after autologous stem cell transplant: Pathologic analysis and comparison with de novo diffuse large B-cell lymphoma', Leukemia and Lymphoma, vol. 50, no. 10, pp. 1625-1631. https://doi.org/10.1080/10428190903128652
Smith, Stephen D. ; Bolwell, Brian J. ; Advani, Anjali S. ; Andresen, Steven W. ; Chan, Josephine L. ; Dean, Robert M. ; Hsi, Eric D. ; Kalaycio, Matt E. ; Pohlman, Brad L. ; Rybicki, Lisa A. ; Sweetenham, John W. / High rate of survival in transformed lymphoma after autologous stem cell transplant : Pathologic analysis and comparison with de novo diffuse large B-cell lymphoma. In: Leukemia and Lymphoma. 2009 ; Vol. 50, No. 10. pp. 1625-1631.
@article{c3a67628e88d4b68900b4f647a157c86,
title = "High rate of survival in transformed lymphoma after autologous stem cell transplant: Pathologic analysis and comparison with de novo diffuse large B-cell lymphoma",
abstract = "Transformed lymphoma (TL) is historically associated with a poor prognosis, though autologous stem cell transplantation (ASCT) has been applied successfully. Better patient selection is needed for this intensive therapy. We analyzed the outcomes between de novo and transformed large B-cell lymphoma in patients undergoing ASCT, with regard to the immunohistochemical (IHC) features of potential prognostic utility including CD10, BCL6, MUM-1, Ki67, and BCL2. Of all patients undergoing ASCT for large B-cell lymphoma at the Cleveland Clinic Taussig Cancer Institute between 2003 and 2008, 56 patients (31 de novo and 25 TL) had undergone detailed IHC analysis. Three-year relapse-free-survival (RFS) and overall survival (OS) for TLvs. patients with de novo large B-cell lymphoma were 64{\%}vs. 59{\%} and 63{\%}vs. 59{\%}, respectively. More patients with TL were characterized as germinal-center B cell-of-origin (92{\%}) than patients with de novo large B-cell lymphoma (71{\%}). Immunohistochemistry did not predict relapse-free or overall survival, and ASCT afforded a high rate of PFS in patients with TL.",
keywords = "Clinical results, Lymphoma and hodgkin disease, Prognostication",
author = "Smith, {Stephen D.} and Bolwell, {Brian J.} and Advani, {Anjali S.} and Andresen, {Steven W.} and Chan, {Josephine L.} and Dean, {Robert M.} and Hsi, {Eric D.} and Kalaycio, {Matt E.} and Pohlman, {Brad L.} and Rybicki, {Lisa A.} and Sweetenham, {John W.}",
year = "2009",
month = "11",
day = "11",
doi = "10.1080/10428190903128652",
language = "English (US)",
volume = "50",
pages = "1625--1631",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - High rate of survival in transformed lymphoma after autologous stem cell transplant

T2 - Pathologic analysis and comparison with de novo diffuse large B-cell lymphoma

AU - Smith, Stephen D.

AU - Bolwell, Brian J.

AU - Advani, Anjali S.

AU - Andresen, Steven W.

AU - Chan, Josephine L.

AU - Dean, Robert M.

AU - Hsi, Eric D.

AU - Kalaycio, Matt E.

AU - Pohlman, Brad L.

AU - Rybicki, Lisa A.

AU - Sweetenham, John W.

PY - 2009/11/11

Y1 - 2009/11/11

N2 - Transformed lymphoma (TL) is historically associated with a poor prognosis, though autologous stem cell transplantation (ASCT) has been applied successfully. Better patient selection is needed for this intensive therapy. We analyzed the outcomes between de novo and transformed large B-cell lymphoma in patients undergoing ASCT, with regard to the immunohistochemical (IHC) features of potential prognostic utility including CD10, BCL6, MUM-1, Ki67, and BCL2. Of all patients undergoing ASCT for large B-cell lymphoma at the Cleveland Clinic Taussig Cancer Institute between 2003 and 2008, 56 patients (31 de novo and 25 TL) had undergone detailed IHC analysis. Three-year relapse-free-survival (RFS) and overall survival (OS) for TLvs. patients with de novo large B-cell lymphoma were 64%vs. 59% and 63%vs. 59%, respectively. More patients with TL were characterized as germinal-center B cell-of-origin (92%) than patients with de novo large B-cell lymphoma (71%). Immunohistochemistry did not predict relapse-free or overall survival, and ASCT afforded a high rate of PFS in patients with TL.

AB - Transformed lymphoma (TL) is historically associated with a poor prognosis, though autologous stem cell transplantation (ASCT) has been applied successfully. Better patient selection is needed for this intensive therapy. We analyzed the outcomes between de novo and transformed large B-cell lymphoma in patients undergoing ASCT, with regard to the immunohistochemical (IHC) features of potential prognostic utility including CD10, BCL6, MUM-1, Ki67, and BCL2. Of all patients undergoing ASCT for large B-cell lymphoma at the Cleveland Clinic Taussig Cancer Institute between 2003 and 2008, 56 patients (31 de novo and 25 TL) had undergone detailed IHC analysis. Three-year relapse-free-survival (RFS) and overall survival (OS) for TLvs. patients with de novo large B-cell lymphoma were 64%vs. 59% and 63%vs. 59%, respectively. More patients with TL were characterized as germinal-center B cell-of-origin (92%) than patients with de novo large B-cell lymphoma (71%). Immunohistochemistry did not predict relapse-free or overall survival, and ASCT afforded a high rate of PFS in patients with TL.

KW - Clinical results

KW - Lymphoma and hodgkin disease

KW - Prognostication

UR - http://www.scopus.com/inward/record.url?scp=70350787139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350787139&partnerID=8YFLogxK

U2 - 10.1080/10428190903128652

DO - 10.1080/10428190903128652

M3 - Article

C2 - 19672775

AN - SCOPUS:70350787139

VL - 50

SP - 1625

EP - 1631

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -